mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.019 |
0.6 |
mRNA |
docetaxel:tanespimycin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.019 |
0.6 |
mRNA |
JQ-1:UNC0638 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.02 |
0.6 |
mRNA |
N9-isopropylolomoucine |
CTRPv2 |
pan-cancer |
AAC |
0.021 |
0.6 |
mRNA |
AT13387 |
CTRPv2 |
pan-cancer |
AAC |
-0.026 |
0.6 |
mRNA |
FSC231 |
CTRPv2 |
pan-cancer |
AAC |
-0.04 |
0.6 |
mRNA |
BRD-K64610608 |
CTRPv2 |
pan-cancer |
AAC |
-0.022 |
0.6 |
mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.02 |
0.6 |
mRNA |
LY-2183240 |
CTRPv2 |
pan-cancer |
AAC |
-0.018 |
0.6 |
mRNA |
hyperforin |
CTRPv2 |
pan-cancer |
AAC |
0.022 |
0.6 |